Phaseline

Companies › Tessa Therapeutics

Tessa Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Mar 2036.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Autologous CD30.CAR-T
CD30-directed CAR-T cell therapy
CD30Phase 2Hodgkin Lymphoma, Adult; Anaplastic Large Cell Lymphoma; Classical Hodgkin LymphomaMar 2036

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04526834Autologous CD30.CAR-TPhase 1Anaplastic Large Cell LymphomaOncologyMar 2036
NCT04268706Autologous CD30.CAR-TPhase 2Hodgkin Lymphoma, AdultOncologyMar 2037
NCT05352828Autologous CD30.CAR-TPhase 1Classical Hodgkin LymphomaOncologyDec 2037

Targets

CD30 (1)

Companies with the same targets

Beijing Biotech

Companies built like this

Vasgene Therapeutics Suzhou BlueHorse Therapeutics Pieris Pharmaceuticals Evaxion Biotech Primmune Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.